



Clopidogrel PredictAR

Predict Adverse Reactions

PHARMACOGENETIC TESTING TO AID IN ASSESSING CLOPIDOGREL EFFICACY

Clopidogrel is a widely used anti-platelet agent for the primary and secondary prevention of arterial thrombosis. Clopidogrel is administered as a pro-drug and is metabolized to its active metabolite by the hepatic cytochrome P450 2C19 (CYP2C19) enzyme. The active metabolite is responsible for the anti-platelet activity of Clopidogrel.

Recent studies demonstrate that DNA variations in the gene for CYP2C19 result in significantly reduced production of the active metabolite of clopidogrel. Additional studies demonstrate that patients with variants in the CYP2C19 gene, including CYP2C19*2 & 3, have reduced production of the active metabolite of clopidogrel, reduced inhibition of platelet aggregation and increased incidence of coronary, cerebrovascular and coronary stent thrombosis.^{2,3,4}

ADVANTAGES OF GENOTYPING IN PREDICTING RESPONSE TO CLOPIDOGREL TREATMENT

- By establishing the CYP2C19 genotype the clinician can now accurately predict if clopidogrel treatment is likely to be effective in the patient requiring anti-platelet therapy.
- In patients currently receiving clopidogrel treatment and in whom a concern exists regarding the potential anti-thrombotic efficacy of this agent determination of CYP2C19 genotype will assist in determining the likely anti-thrombotic benefit of established clopidogrel treatment.

SPECIMEN REQUIREMENTS

Test Name: Clopidogrel PredictAR (CYP2C19)

Sample Required: 4ml EDTA whole blood (Buccal swab also accepted)

Test Frequency: Daily (Mon-Fri)

Please note that these tests are not Medicare rebateable.

REFERENCES

1. Hulot JS, Bura A, Villard E et al. Blood. 2006;108:2244-7
2. Collet JP, Hulot JS, Pena A et al. Lancet. 2009;373:309-17
3. Mega JL, Close SL, Wiviott SD et al. N Eng J Med. 2009;360
4. Tabassome S, Verstuyft C, Mary-Krause M et al. N Eng J Med. 2009;360

If you have any questions or require further information, please contact our Customer Service Centre.

1300 453 688

Providing services since 1936, Healthscope Pathology operates throughout Australia, New Zealand, Singapore and Malaysia.

Healthscope Pathology has purpose built, state-of-the-art service and molecular research laboratories which ensure the highest standard of testing.

focused on you

healthscopepathology.com.au

HAP-1064-W-002 (07/10)
Clinical Laboratories Pty Ltd ABN 62 006 823 089